Introduction

Background
Systemic sclerosis (SSc) is a heterogeneous autoimmune rheumatic disease that falls within the SSc spectrum of disorders. It is characterized by fibrosis of the skin and internal organs together with vascular manifestations includ ' s phenomenon, digital ischemia, pulmonary arterial hypertension and renal crisis. Within UK, SSc has an annual incidence of 3.7/million and a prevalence of 31-88/million with a peak age of onset of 40-50 years. Recent classification criteria have been developed and major disease subsets are recognized, notably limited or diffuse cutaneous subsets [1] . It can occur in overlap with other autoimmune rheumatic diseases.
Need for guidelines
SSc is a complex, multi-organ disease associated with a high morbidity and mortality and a comprehensive multidisciplinary guideline is therefore required. This guideline will therefore provide advice and rationale for health professionals in making choices and decisions in managing this disease. European League against Rheumatism (EULAR) has published a summary of evidence-based recommendations for management of SSc [2] .
Target audience
The target audience is rheumatologists, dermatologists, general physicians and organ based specialists treating complications of SSc including nephrologists, cardiologists, gastroenterologists, respiratory physicians, cardiologists as well at trainees, specialist nurses and other healthcare professionals.
Methodology
This guideline was developed in accordance with the current BSR Standards Audit and Guidelines working group (SAGWG) protocol for developing evidence based guidelines. A comprehensive literature review was undertaken using the PUBMED and MEDLINE databases for English-language J hin the guideline.
Further relevant papers were identified from the reference lists of retrieved articles. Two reviewers independently extracted information from each study.
The literature reviews were used to inform and underpin discussion during a series of face to face meetings and telephone conference calls as the guideline was developed and drafted. Designated members of the group took the lead on each section of the guideline which was then refined and approved by consensus. An associated executive summary represents a summary of the full guideline document. The recommendations were graded for level of evidence and strength by the working party according to the Royal C P C G G P (http://www.rcplondon.ac.uk/resources/clinical-resources/concise-guidance-good-practice). Based on the level of evidence and the strength of the recommendation, each recommendation was subjected to a vote and a minimum 75% agreement was considered as consensus.
It is expected that the guideline will be updated after 5 years or earlier if there is significant development in key areas in management of SSc.
Eligibility and exclusion criteria
Patients are classified as having a diagnosis SSc based on current classification criteria (ACR/EULAR 
Part A: General approach to SSc management
The heterogeneous nature of SSc is an important consideration in management since the timing and frequency of the development of specific features of SSc varies. Operationally the key issues are the diagnosis of SSc, the classification into major subsets based upon the extent of skin sclerosis, the potential use of other criteria to subgroup patients with SSc in meaningful ways and the definition of onset of the disease which has relevance especially for clinical research and trial recruitment. SSc can be divided into distinct subsets of disease. The major subsets of limited and diffuse cutaneous SSc based upon the extent of skin thickening. Overlap SSc cases that account for up to 20% of cases in many published cohorts and can be classified as limited or diffuse SSc but more often fit into the limited skin subset. Figure 1 summarises a general approach to management of SSc that is informed by this guideline and the key source references and internet links are summarised for individual classes of treatment in Table 1 .
Importance of early diffuse SSc current priorities and approach
Management of early diffuse cutaneous SSc (dcSSc) must occur within the framework of a multidisciplinary team and this permits broad approach, education and medical and non-medical aspects of the disease to be addressed. In general there needs to be a baseline assessment of internal organ function and attention to symptomatic treatment of common or universal symptoms ' -oesophageal reflux and pruritus. Most important though is consideration of initiation of immunosuppressive therapy that may modify skin and internal organ manifestations. Any patient with dcSSc of less than 3 years duration should be considered for treatment with a broad-spectrum immunosuppressive agent, although the evidence base for this approach is weak [2] . The currently used agents include mycophenolate (MMF), methotrexate (MTX) and cyclophosphamide (CYC). There is some evidence base to support the use of these agents but few controlled trials and other agents are under evaluation. Observational cohort studies and retrospective case series have been published. Outcome assessment is confounded by natural history of dcSSc and this is variable. However it is clear that there is substantial capacity for spontaneous improvement in skin disease as this has been observed in many patients enrolled into the placebo arm of randomised controlled trials [3] . Early identification of suspected cases of dcSSc is important and all of these patients should be seen in a specialist SSc centre although shared care with local specialists is usually the most appropriate strategy and this is central to the long-term management plan of these patients.
Recommendations in management of early systemic sclerosis:
 Early recognition and diagnosis of dcSSc is a priority with referral to a specialist SSc centre.
Patients with early dcSSc should be offered an immunosuppressive agent RP is characterized by vasospasm affecting the extremities on exposure to change in ambient temperatures or emotional stressors leading to acral ischaemia [8] . The attacks typically present with triphasic colour changes, initially with pallor due to vasoconstriction evolving to the cyanotic blue phase and finally the painful reactive hyperaemic phase [9] ). It is clinically important to differentiate primary RP (PRP) in which there is no underlying medical condition from RP secondary to another disease (SRP). Among the rheumatic diseases, SSc has the highest frequency of RP and it often precedes the onset of other features of SSc. The interval between RP and onset of other SScspecific symptoms is generally longer for limited cutaneous SSc than dcSSc [10] .
Digital ulcers typically occur as a result of poor tissue perfusion over the digital pulps, around the nailfold and on extensor surfaces of the fingers or toes (in particular over the small joints) but may also occur in relation to calcinosis. Around half of patients with SSc [11] report a history of digital ulceration, often occurring within the first year of the disease [12] . Digital ulcers are associated with significant impact on function and quality of life [13] and impact negatively on occupation [14] with greater requirement for paid and unpaid help [15] . Severe DU are those causing or threatening tissue destruction or when 3 or more occur in one year. These need advanced therapy such as sildenafil.
Recom R
• A that patient education, specifically general/lifestyle measures including keeping warm, the avoidance of cold ambient environments and smoking cessation, are key aspects of management. Final consensus: 100%.
• First line treatments are calcium channel blockers (Ia,A) and angiotensin II receptor antagonists (Ib,C) Final consensus 100%.
• Other treatments that may be considered if these are either ineffective or not tolerated are:
selective serotonin reuptake inhibitors, alpha-blockers and statin therapy (III,C) Final consensus 100%.
• 
Lung fibrosis
Pulmonary complications are the commonest cause of death related to SSc [16] . SSc-ILD may affect patients with diffuse or limited cutaneous SSc in equal frequency. Those with certain subtype antibodies including anti-Scl70 antibodies, anti-U11/U12 ribonucleoprotein (RNP) antibodies or antiTh/To RNP antibodies are more likely to develop ILD. Up to 80% of SSc patients will develop ILD and it is clinically significant in approximately a third of patients. Deterioration in lung function tends to occur early in the disease i.e. within 5 years of the first non-' " found in their historical cohort that after 3 years more than 50% of patients with SSc had developed a FVC of less than 55% predicted [17] .
Recommendations for lung fibrosis in systemic sclerosis
 All SSc cases should be evaluated for lung fibrosis. Treatment is determined by extent and severity and likelihood of progression to severe disease (I, A) Final consensus 90%
 Cyclophosphamide by IV infusion is recommended (I, A/B) and MMF may also be used as an alternative or following cyclophosphamide (II, B) Final consensus 90%.
Pulmonary arterial hypertension
Pulmonary arterial hypertension is defined as a mean pulmonary arterial pressure ( 
Gut disease
The gastrointestinal (GI) tract is the most frequent internal organ system affected by SSc and is responsible for substantial morbidity. This guideline focuses on the evidence for the drug treatment of gut disease and not its screening, investigation or overall management (which is covered by the UKSSG consensus best practice recommendation on gastrointestinal involvement [18] ).
Recommendations for gastrointestinal manifestations in systemic sclerosis
The following therapeutic approaches and drugs are considered by experts to be of value in treatment of GI tract complications of SSc:
• Proton pump inhibitors and Histamine H2 receptor antagonists are recommended for treatment of gastro-oesophageal reflux and dysphagia and may require maintenance therapy (III, C) Final consensus 100%
• Prokinetic dopamine agonists may be used for dysphagia and reflux (III, C) Final consensus 90%.
• Parenteral nutrition should be considered for patients with severe weight loss refractory to enteral supplementation (III, C) Final consensus 100%
• Intermittent broad spectrum oral antibiotics (e.g. ciprofloxacin) are recommended for intestinal overgrowth and rotational regimes may be helpful (III, C) Final consensus 100%
• Anti-diarrhoeal agents (e.g. loperamide) or laxatives may be used for symptomatic management of diarrhoea or constipation which often alternate as clinical problems (III, C) (Final consensus 100%).
Renal complications
SSc renal crisis (SRC) is a severe and life-threatening complication of SSc, estimated to affect 5 10% of all patients [19] , predominantly in the diffuse subset [20] . Several studies identified a number of risk factors that predict the occurrence of SRC [21, 22] . Among these are SSc duration < 4 years, diffuse and rapidly progressive skin thickening, new anaemia, new cardiac events (e.g., pericardial effusion or congestive heart failure), anti-RNA-polymerase III antibodies and corticosteroid therapy (prednisone >15 mg/d)(III,C) Final consensus 80% [19] .
Recommendations for treatment of scleroderma renal crisis:
• Patients at risk of SRC should be followed closely and their blood pressure monitored at least weekly.
• Prompt recognition of SRC and initiation of therapy with an ACE inhibitor offers the best opportunity for a good outcome (III, C) Final consensus 90%.
• Other anti-hypertensive agents may be considered for managing refractory hypertension in conjunction with ACEi in SRC (III, C) Final consensus 90%.
Cardiac disease
Clinically evident cardiac involvement is associated with a poor prognosis [23, 24] and a large proportion of SSc-related fatalities are attributable to cardiac causes [25, 26] . Whilst fibrosis is a central feature of SSc, clinical and pathological evidence suggests microvascular dysfunction is a primary process and one of the earliest features of disease. Myocardial fibrosis can affect the endocardium, myocardium and pericardium explaining the varied clinical presentations [27, 28] . Of note, these recommendations relate to primary myocardial involvement as opposed to right heart involvement and pulmonary hypertension that are discussed elsewhere in this guideline.
Recommendations for treatment of cardiac manifestations of systemic sclerosis:
Although the published evidence base is limited, experts have recommended the following treatment approach for cardiac complications of SSc. 
Skin manifestations
Management of skin disease is an intrinsic aspect of management of SSc. Pruritus is a common and particularly troublesome in early stage diffuse cutaneous SSc and becomes less intrusive once the disease plateaus. Cutaneous telangiectasia may be widespread especially over the hands and face and may present as a major cosmetic problem [29, 30] . Immunosuppression that aims to modify the disease is also likely to impact on skin involvement but it is also important to consider the evidence based management for cutaneous manifestations of SSc per se. The evidence base and treatment options for individual skin manifestations are outlined below.
Recommendations for skin manifestations in systemic sclerosis:
 Practical approaches in particular maintaining adequately moisturised skin is essential, especially moisturisers that are lanolin-based. It is strongly recommended to avoid frequent bathing with harsh deodorants soaps and non-soap cleansers should be used where possible (III, C) Final consensus 100%.
 Antihistamines are often used for itch (III,C). Final consensus 90%.
 Current treatment options for telangiectasia include skin camouflage and laser or intense pulsed light therapy [31, 32] (III,C) Final consensus 100%.
Calcinosis in SSc
There is a very limited evidence base (mainly case reports and small series) to guide clinicians on the management of calcinosis in patients with SSc and none of the therapies listed below have positive trial data to support routine use making this a key area in need of research [33] .
Recommendations for treatment of calcinosis in systemic sclerosis
 Superadded infection of calcinosis should be recognised early and treated with appropriate 
Musculoskeletal manifestations
Musculoskeletal complications in SSc are common and debilitating and can occur either as a primary manifestation of the condition or as a result of an overlap disorder with another autoimmune rheumatic disease (ARD). For the latter, a recent study from a single-centre cohort showed that a fifth of patients with SSc have a coexisting ARD: a third had rheumatoid arthritis and another 40%
had myositis [34] . Primary involvement occurs due to deformity and restricted movement of joints, tendon or soft tissue contractures and fibrosis or inflammatory changes in or around tendons and joints and involvement of skeletal muscle.
There is limited evidence to support specific treatment of musculoskeletal involvement but it is likely that these manifestations will benefit from treatments given for skin or other manifestations especially as the agents used are in widespread use for treatment of other forms of inflammatory musculoskeletal disease.
Recommendations for musculoskeletal manifestations in systemic sclerosis:
 Musculoskeletal manifestations of SSc may benefit from immunomodulatory treatments given for other aspects of the disease such as skin (III, C) Final consensus 100%. 
Autologous stem cell transplantation (ASCT) as a treatment for poor prognosis early dcSSc
The principle of autologous ASCT in autoimmune diseases is the ablation of an aberrant or selfreactive immune system using high-dose chemotherapy and/or lymphoablative antibodies or total body irradiation (TBI) and regeneration of a new immune system from hematopoietic stem cells [35] . The combination of high dose CYC and anti-thymocyte globulin (ATG) is considered a nonmyeloablative ASCT, leaving bone marrow stem cells intact, whereas the use of TBI and chemotherapeutic agents such as busulfan renders conditioning myeloablative, depending on the doses used. Haematopoietic stem cells transplant registry data, several case reports and pilot studies in the USA [36, 37] and Europe [38, 39] involving patients with dcSSc demonstrated a rapid clinical improvement of functional performance, skin thickening and stabilisation of major organ function, but at the cost of high treatment-related toxicity and mortality [40] . To understand the effect of ASCT on SSc patients three randomised controlled trials have been designed to date.
Efficacy, safety and long-term side effects of autologous ASCT in SSc have been studied. Eight deaths (10%) in the HSCT group were considered treatment-related by the independent data monitoring committee and none died from treatment related causes in the control group, most deaths in the last group occurred due to progressive disease.
Despite 10% treatment-related mortality, long term event-free survival and overall survival were significantly better in the HSCT group than in the group treated with IV pulse cyclophosphamide. The
in North America is ongoing (see ClinicalTrials.gov (NCT00114530)).
Recommendation for autologous stem cell transplantation in systemic sclerosis:
 Current evidence support the use of ASCT in poor prognosis diffuse SSc that does not have severe internal organ manifestations that render the treatment highly toxic (Ib, B) Final consensus 80%.
 Definitive statements regarding relative safety and efficacy compared with other immunosuppressive strategies and definition of appropriate cases for ASCT will require further data (III,C) Final consensus 90%.
Non-drug interventions
Although the main focus of this guideline is pharmacological treatment for SSc it is clear that other approaches to management are also used and that these may be complementary to drug therapy.
There is evidence to support the use of physical therapy and connective tissue massage and also other formal programmes to increase exercise capacity. These may be delivered in the hospital setting or within the community. Although the formal evidence base is quite limited there was strong feeling from patient representatives and those professionals involved in delivering such interventions that they have merit and are generally well tolerated.
Recommendation for non-drug interventions in systemic sclerosis:
 Although there are very few studies the opinion of the group was that non-drug interventions may be helpful in SSc and are generally not detrimental.
 Specialist experience of SSc cases is likely to make non-drug interventions more effective and these approaches are popular with patients and can be expected to impact positively on the disease. More research is needed in this area (III, D) Final consensus 100%.
Part C. Service organization and delivery within NHS England
Systemic sclerosis must be diagnosed promptly, investigated appropriately and managed within an system that support patients with SSc need to tailor to their needs and respond promptly as uncontrolled disease can lead to accrual organ damage and in some cases, these crises may be lifethreatening. Such systems may be available at different levels in primary or secondary care, provided by clinical nurse specialists or consultants as appropriate. Some services that are required are already commissioned within specialist centres including pulmonary hypertension, home parenteral nutrition, haemopoietic stem cell transplantation and dialysis services for renal failure. These provide a template for delivery of care but it is important that specialist centres are familiar with the particular challenges posed by SSc and its multisystem nature and high burden of complications and co-morbidity.
Quality standards and audit tool
SSc is an uncommon condition and the heterogeneous nature of the disease with multisystem involvement pose significant challenges in management of these patients. This guideline aimed to focus on key elements in assessment and treatment of both specific complications and general aspects of the disease. The quality standards and audit tool therefore relate to these core elements of patient care and service delivery. vi. There should be opportunity to participate in clinical research projects, registries specific to specialized treatments and clinical trials to improve quality of care and help others in the future. iii. Proportion of patients having PDE5 (e.g. sildenafil)for digital ulcer disease. Standard 10%-50%.
Mechanism for audit of the guideline
iv. Proportion of patients referred for invasive investigation for pulmonary hypertension. 
